Myocardial-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure

European Heart Journal

Volumn 31, Issue 14, 2010, Pages 1722-1729

  Gaemperli, Oliver ^a,b   Liga, Riccardo ^a,b   Spyrou, Nicos ^a,b   Rosen, Stuart D ^a,b   Foale, Rodney ^a,b   Kooner, Jaspal S ^a,b   Rimoldi, Ornella E ^a,b   Camici, Paolo G ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adrenoceptor; Congestive heart failure; Myocardial infarction; Positron emission tomography; Prognosis; S 11C CGP 12177

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE C11; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBON 11; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; OXYGEN 15; UNCLASSIFIED DRUG; WATER; DIAGNOSTIC AGENT; PROPANOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART MUSCLE; HEART MUSCLE BLOOD FLOW; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEPTOR DOWN REGULATION; SYMPTOM; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; HEART; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CORONARY CIRCULATION; DOWN-REGULATION; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; PROPANOLAMINES; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA; VENTRICULAR REMODELING;

EID: 77954806910     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq138     Document Type: Article

References (37)

1. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-e82.
2. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, McDonagh TA, Cowie MR. Improving survival in the six months after diagnosis of heart failure in the past decade: population-based data from the UK. Heart 2009;95:1851-1856.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
5. Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER Jr, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 1993;22:368-375.
6. Zipes DP. Influence of myocardial ischemia and infarction on autonomic inner-vation of heart. Circulation 1990;82:1095-1105.
7. Leenen FH. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ Res 2007;101:221-223.
8. Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, Esler MD. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation 1995;92:1813-1818.
9. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803-815.
10. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302.
11. Schafers M, Dutka D, Rhodes CG, Lammertsma AA, Hermansen F, Schober O, Camici PG. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998;82:57-62.
12. Merlet P, Delforge J, Syrota A, Angevin E, Maziere B, Crouzel C, Valette H, Loisance D, Castaigne A, Rande JL. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993;87:1169-1178.
13. Spyrou N, Rosen SD, Fath-Ordoubadi F, Jagathesan R, Foale R, Kooner JS, Camici PG. Myocardial beta-adrenoceptor density one month after acute myo-cardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 2002;40:1216-1224.
14. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
15. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 1999;40:1848-1856.
16. Lefroy DC, de Silva R, Choudhury L, Uren NG, Crake T, Rhodes CG, Lammertsma AA, Boyd H, Patsalos PN, Nihoyannopoulos P, Oakley CM, Jones T, Camici PG. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol 1993;22:1653-1660.
17. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med 2009;50:1076-1087.
18. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Fra-mingham study. J Am Coll Cardiol 1993;22:6A-13A.
19. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653.
20. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003;42:1446-1453.
21. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356: 830-840.
22. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA. Long-term prognostic value of 13N-ammonia myocar-dial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150-156.
23. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-1035.
24. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, Gallopin M, Salvadori P, Sorace O, Carpeggiani C, Poddighe R, L'Abbate A, Parodi O. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-193.
25. Caldwell JH, Link JM, Levy WC, Poole JE, Stratton JR. Evidence for pre-to post-synaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. J Nucl Med 2008;49:234-241.
26. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-463.
27. Mann DL, Kent RL, Parsons B, Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
28. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-385.
29. Camici PG. Imaging of cardiac adrenergic innervation. Heart 2002;88:209-210.
30. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001;42:1062-1076.
31. Choudhury L, Guzzetti S, Lefroy DC, Nihoyannopoulos P, McKenna WJ, Oakley CM, Camici PG. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 1996;75:50-54.
32. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-477.
33. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, Loisance D, Castaigne A, Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-923.
34. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, Gourgon R, Merlet P. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-766.
35. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, Unlu M, Estorch M, Banerjee G, Jacobson AF. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-546.
36. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-121.
37. de Jong RM, Willemsen AT, Slart RH, Blanksma PK, van Waarde A, Cornel JH, Vaalburg W, van Veldhuisen DJ, Elsinga PH. Myocardial beta-adrenoceptor down-regulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. Eur J Nucl Med Mol Imaging 2005;32: 443-447.